NYSE:GMED - New York Stock Exchange, Inc. - US3795772082 - Common Stock - Currency: USD
NYSE:GMED (5/30/2025, 2:39:56 PM)
59.1
+0.21 (+0.36%)
The current stock price of GMED is 59.1 USD. In the past month the price decreased by -17.95%. In the past year, price decreased by -12.25%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.97 | 232.62B | ||
ISRG | INTUITIVE SURGICAL INC | 72.15 | 197.57B | ||
BSX | BOSTON SCIENTIFIC CORP | 38.8 | 154.99B | ||
SYK | STRYKER CORP | 30.42 | 145.69B | ||
MDT | MEDTRONIC PLC | 15.06 | 106.26B | ||
BDX | BECTON DICKINSON AND CO | 12.28 | 49.57B | ||
EW | EDWARDS LIFESCIENCES CORP | 29.94 | 45.66B | ||
IDXX | IDEXX LABORATORIES INC | 45.02 | 41.59B | ||
RMD | RESMED INC | 26.95 | 35.88B | ||
DXCM | DEXCOM INC | 52.1 | 33.71B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.2 | 32.01B | ||
STE | STERIS PLC | 26.2 | 24.04B |
Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The company is headquartered in Audubon, Pennsylvania and currently employs 5,300 full-time employees. The company went IPO on 2012-03-08. The firm offers a portfolio of differentiated technologies that are used to treat a variety of musculoskeletal conditions. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the conditions affecting the spine, including degenerative conditions, deformities, tumors, and trauma. The company provides solutions that facilitate both open and minimally invasive surgery techniques. The company includes traditional fusion implants, such as pedicle screws and rod systems, and others. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip.
GLOBUS MEDICAL INC - A
2560 General Armistead Ave
Audubon PENNSYLVANIA 19403 US
CEO: David M. Demski
Employees: 5300
Phone: 16109301800
The current stock price of GMED is 59.1 USD. The price increased by 0.36% in the last trading session.
The exchange symbol of GLOBUS MEDICAL INC - A is GMED and it is listed on the New York Stock Exchange, Inc. exchange.
GMED stock is listed on the New York Stock Exchange, Inc. exchange.
22 analysts have analysed GMED and the average price target is 99.41 USD. This implies a price increase of 68.21% is expected in the next year compared to the current price of 59.1. Check the GLOBUS MEDICAL INC - A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GLOBUS MEDICAL INC - A (GMED) has a market capitalization of 8.00B USD. This makes GMED a Mid Cap stock.
GLOBUS MEDICAL INC - A (GMED) currently has 5300 employees.
GLOBUS MEDICAL INC - A (GMED) has a support level at 56.27 and a resistance level at 61.26. Check the full technical report for a detailed analysis of GMED support and resistance levels.
The Revenue of GLOBUS MEDICAL INC - A (GMED) is expected to grow by 12.88% in the next year. Check the estimates tab for more information on the GMED EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GMED does not pay a dividend.
GLOBUS MEDICAL INC - A (GMED) will report earnings on 2025-08-04, after the market close.
The PE ratio for GLOBUS MEDICAL INC - A (GMED) is 19.06. This is based on the reported non-GAAP earnings per share of 3.1 and the current share price of 59.1 USD. Check the full fundamental report for a full analysis of the valuation metrics for GMED.
The outstanding short interest for GLOBUS MEDICAL INC - A (GMED) is 3.76% of its float. Check the ownership tab for more information on the GMED short interest.
ChartMill assigns a fundamental rating of 6 / 10 to GMED. GMED is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
Over the last trailing twelve months GMED reported a non-GAAP Earnings per Share(EPS) of 3.1. The EPS increased by 23.02% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 7.39% | ||
ROA | 3.94% | ||
ROE | 4.54% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 80% to GMED. The Buy consensus is the average rating of analysts ratings from 22 analysts.
For the next year, analysts expect an EPS growth of 6.18% and a revenue growth 12.88% for GMED